Radiopharmaceuticals

Researching Radiosensitizers, a New Class of Drugs That Would Make Tumors More Vulnerable to Radiation Therapy

Two out of three cancer patients are treated with radiation, but the therapy often fails to wipe out the tumor or slow its growth. Southern Research is working to develop a new class of drugs that will help the radiation deliver a more powerful punch to the disease. Dr. Bo Xu, M.D., Ph.D., Distinguished Fellow […]

Pharmaceutical Business News Radiopharmaceuticals

Q BioMed Gears up for Production of Cancer Pain Palliation Drug with Commercial Launch Expected in Q2 2017

Q BioMed Inc, a NYC-based biomedical acceleration and development company has begun process validation for the manufacturing of a non-narcotic analgesic treatment for pain associated with metastatic bone cancer. The drug, a generic Strontium Chloride 89 injection, provides long-lasting relief for patients suffering from debilitating bone pain due to metastatic cancer, typically caused by advanced-stage […]

cancer Cell Therapy Radiopharmaceuticals

Antibody Drug Conjugates May Help Personalize Radiotherapy For Patients With Cancer

Many types of cancer become drug resistant, making them difficult to treat. Researchers with University of California San Diego School of Medicine and Moores Cancer Center have identified a strategy to selectively sensitize certain cancer cells to radiation therapy that may improve tumor control and reduce treatment-related side effects. In a paper published October 4 […]

Biotechnology cancer Clinical Trials Radiopharmaceuticals

FDA Greenlights Orphan Drug Status for Radioimmuneconjugate for Treating Refractory and Relapsed Acute Myeloid Leukemia in Elderly Patients

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Iomab-B, a radioimmunotherapeutic that conditions relapsed and refractory Acute Myeloid Leukemia (AML) patients for a Hematopoietic Stem Cell Transplant (HSCT), commonly referred to as a Bone Marrow Transplant (BMT). Iomab-B will soon begin a 150 patient, pivotal Phase 3 multicenter trial in […]

Radiopharmaceuticals rare diseases

Pharma Company Funds Saint Louis University Researcher’s Quest to Treat His Daughter’s Disease

A team of Saint Louis University scientists led by Fran Sverdrup, Ph.D., developing a treatment for his daughter’s muscular dystrophy, has new funding for their research, thanks in part to a California-based biopharmaceutical company named Ultragenyx, which is focused on the development of novel products for rare and ultra-rare diseases. SLU’s Center for World Health […]